Tumor necrosis factor (TNF) is a multifunctional cytokine that plays important roles in diverse cellular events such as cell survival, proliferation, differentiation, and death. As a pro-inflammatory cytokine, TNF is secreted by inflammatory cells, which may be involved in inflammation-associated carcinogenesis. TNF exerts its biological functions through activating distinct signaling pathways such as nuclear factor-κB (NF-κB) and c-Jun N-terminal kinase (JNK). NF-κB is a major cell survival signal that is anti-apoptotic, whereas sustained JNK activation contributes to cell death. The crosstalk between the NF-κB and JNK is involved in determining cellular outcomes in response to TNF. In regard to cancer, TNF is a double-dealer. On one hand, TNF could be an endogenous tumor promoter, because TNF stimulates the growth, proliferation, invasion and metastasis, and tumor angiogenesis of cancer cells. On the other hand, TNF could be a cancer killer. The property of TNF in inducing cancer cell death renders it a potential cancer therapeutic, although much work is needed to reduce its toxicity for systematic TNF administration. Recent studies have focused on sensitizing cancer cells to TNF-induced apoptosis through inhibiting survival signals such as NF-κB, by combined therapy. In this article we provide an overview of the roles of TNF-induced signaling pathways in cancer biology with specific emphasis on carcinogenesis and cancer therapy.
Matthews N, Watkins JF . Tumour-necrosis factor from the rabbit. I. Mode of action, specificity and physicochemical properties. Br J Cancer 1978; 38: 302–9.
Green S, Dobrjansky A, Chiasson MA . Murine tumor necrosis-inducing factor: purification and effects on myelomonocytic leukemia cells. J Natl Cancer Inst 1982; 68: 997–1003.
Aggarwal BB . Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 2003; 3: 745–56.
Wajant H, Pfizenmaier K, Scheurich P . Tumor necrosis factor signaling. Cell Death Differ 2003; 10: 45–65.
Devin A, Cook A, Lin Y, Rodriguez Y, Kelliher M, Liu Z . The distinct roles of TRAF2 and RIP in IKK activation by TNF-R1: TRAF2 recruits IKK to TNF-R1 while RIP mediates IKK activation. Immunity 2000; 12: 419–29.
Yang J, Lin Y, Guo Z, Cheng J, Huang J, Deng L, et al. The essential role of MEKK3 in TNF-induced NF-kappaB activation. Nat Immunol 2001; 2: 620–4.
Karin M, Yamamoto Y, Wang QM . The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov 2004; 3: 17–26.
Kamata H, Honda S, Maeda S, Chang L, Hirata H, Karin M . Reactive oxygen species promote TNF alpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell 2005; 120: 649–61.
Devin A, Lin Y, Liu ZG . The role of the death-domain kinase RIP in tumour-necrosis-factor-induced activation of mitogen-activated protein kinases. EMBO Rep 2003; 4: 623–7.
Liu ZG, Hsu H, Goeddel DV, Karin M . Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death. Cell 1996; 87: 565–76.
Liu J, Lin A . Role of JNK activation in apoptosis: a double-edged sword. Cell Res 2005; 15: 36–42.
Lin A, Dibling B . The true face of JNK activation in apoptosis. Aging Cell 2002; 1: 112–6.
Ventura JJ, Cogswell P, Flavell RA, Baldwin AS Jr, Davis RJ . JNK potentiates TNF-stimulated necrosis by increasing the production of cytotoxic reactive oxygen species. Genes Dev 2004; 18: 2905–15.
Wang X . The expanding role of mitochondria in apoptosis. Genes Dev 2001; 15: 2922–33.
Wajant H . Death receptors. Essays Biochem 2003; 39: 53–71.
Petersen SL, Wang L, Yalcin-Chin A, Li L, Peyton M, Minna J, et al. Autocrine TNF alpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell 2007; 12: 445–56.
Wang L, Du F, Wang X . TNF-alpha induces two distinct caspase-8 activation pathways. Cell 2008; 133: 693–703.
Lin Y, Choksi S, Shen HM, Yang QF, Hur GM, Kim YS, et al. Tumor necrosis factor-induced nonapoptotic cell death requires receptor-interacting protein-mediated cellular reactive oxygen species accumulation. J Biol Chem 2004; 279: 10822–8.
Holler N, Zaru R, Micheau O, Thome M, Attinger A, Valitutti S, et al. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat Immunol 2000; 1: 489–95.
Degterev A, Hitomi J, Germscheid M, Ch'en IL, Korkina O, Teng X, et al. Identification of RIP 1 kinase as a specific cellular target of necrostatins. Nat Chem Biol 2008; 4: 313–21.
Kim YS, Morgan MJ, Choksi S, Liu ZG . TNF-induced activation of the Noxl NADPH oxidase and its role in the induction of necrotic cell death. Mol Cell 2007; 26: 675–87.
Lin Y, Devin A, Rodriguez Y, Liu ZG . Cleavage of the death domain kinase RIP by caspase-8 prompts TNF-induced apoptosis. Genes Dev 1999; 13: 2514–26.
Ferrajoli A, Keating MJ, Manshouri T, Giles FJ, Dey A, Estrov Z, et al. The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia. Blood 2002; 100: 1215–9.
Ahmed MI, Salahy EE, Fayed ST, El-Hefnawy NG, Khalifa A . Human papillomavirus infection among Egyptian females with cervical carcinoma: relationship to spontaneous apoptosis and TNF-alpha. Clin Biochem 2001; 34: 491–8.
Szlosarek PW, Grimshaw MJ, Kulbe H, Wilson JL, Wilbanks GD, Burke F, et al. Expression and regulation of tumor necrosis factor alpha in normal and malignant ovarian epithelium. Mol Cancer Ther 2006; 5: 382–90.
Michalaki V, Syrigos K, Charles P, Waxman J . Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer 2004; 90: 2312–6.
Tselepis C, Perry I, Dawson C, Hardy R, Darnton SJ, McConkey C, et al. Tumour necrosis factor-alpha in Barrett's oesophagus: a potential novel mechanism of action. Oncogene 2002; 21: 6071–81.
Garcia-Tunon I, Ricote M, Ruiz A, Fraile B, Paniagua R, Royuela M . Role of tumor necrosis factor-alpha and its receptors in human benign breast lesions and tumors (in situ and infiltrative). Cancer Sci 2006; 97: 1044–9.
Berberoglu U, Yildirim E, Celen O . Serum levels of tumor necrosis factor alpha correlate with response to neoadjuvant chemotherapy in locally advanced breast cancer. Int J Biol Markers 2004; 19: 130–4.
Kim S, Keku TO, Martin C, Galanko J, Woosley JT, Schroeder JC, et al. Circulating levels of inflammatory cytokines and risk of colorectal adenomas. Cancer Res 2008; 68: 323–8.
Bel Hadj Jrad B, Chatti A, Laatiri A, Ahmed SB, Romdhane A, Ajimi S, et al. Tumor necrosis factor promoter gene polymorphism associated with increased susceptibility to non-Hodgkin's lymphomas. Eur J Haematol 2007; 78: 117–22.
Rothman N, Skibola CF, Wang SS, Morgan G, Lan Q, Smith MT, et al. Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol 2006; 7: 27–38.
Ho SY, Wang YJ, Chen HL, Chen CH, Chang CJ, Wang PJ, et al. Increased risk of developing hepatocellular carcinoma associated with carriage of the TNF2 allele of the -308 tumor necrosis factor-alpha promoter gene. Cancer Causes Control 2004; 15: 657–63.
Machado JC, Figueiredo C, Canedo P, Pharoah P, Carvalho R, Nabais S, et al. A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma. Gastroenterology 2003; 125: 364–71.
Duarte I, Santos A, Sousa H, Catarino R, Pinto D, Matos A, et al. G-308A TNF-alpha polymorphism is associated with an increased risk of invasive cervical cancer. Biochem Biophys Res Commun 2005; 334: 588–92.
Garrity-Park MM, Loftus EV Jr, Bryant SC, Sandborn WJ, Smyrk TC . Tumor necrosis factor-alpha polymorphisms in ulcerative colitis-associated colorectal cancer. Am J Gastroenterol 2008; 103: 407–15.
Shih CM, Lee YL, Chiou HL, Chen W, Chang GC, Chou MC, et al. Association of TNF-alpha polymorphism with susceptibility to and severity of non-small cell lung cancer. Lung Cancer 2006; 52: 15–20.
Azmy IA, Balasubramanian SP, Wilson AG, Stephenson TJ, Cox A, Brown NJ, et al. Role of tumour necrosis factor gene polymorphisms (-308 and -238) in breast cancer susceptibility and severity. Breast Cancer Res 2004; 6: R395–400.
Juszczynski P, Kalinka E, Bienvenu J, Woszczek G, Borowiec M, Robak T, et al. Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcome. Blood 2002; 100: 3037–40.
Jang WH, Yang YI, Yea SS, Lee YJ, Chun JH, Kim HI, et al. The -238 tumor necrosis factor-alpha promoter polymorphism is associated with decreased susceptibility to cancers. Cancer Lett 2001; 166: 41–6.
Wu MS, Chen LT, Shun CT, Huang SP, Chiu HM, Wang HP, et al. Promoter polymorphisms of tumor necrosis factor-alpha are associated with risk of gastric mucosa-associated lymphoid tissue lymphoma. Int J Cancer 2004; 110: 695–700.
Purdue MP, Lan Q, Kricker A, Grulich AE, Vajdic CM, Turner J, et al. Polymorphisms in immune function genes and risk of non-Hodgkin lymphoma: findings from the New South Wales non-Hodgkin Lymphoma Study. Carcinogenesis 2007; 28: 704–12.
Hellmig S, Fischbach W, Goebeler-Kolve ME, Folsch UR, Hampe J, Schreiber S . A functional promotor polymorphism of TNF-alpha is associated with primary gastric B-Cell lymphoma. Am J Gastroenterol 2005; 100: 2644–9.
Popivanova BK, Kitamura K, Wu Y, Kondo T, Kagaya T, Kaneko S, et al. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest 2008; 118: 560–70.
Zhaorigetu S, Yanaka N, Sasaki M, Watanabe H, Kato N . Silk protein, sericin, suppresses DMBA-TPA-induced mouse skin tumori-genesis by reducing oxidative stress, inflammatory responses and endogenous tumor promoter TNF-alpha. Oncol Rep 2003; 10: 537–43.
Scott KA, Moore RJ, Arnott CH, East N, Thompson RG, Scallon BJ, et al. An anti-tumor necrosis factor-alpha antibody inhibits the development of experimental skin tumors. Mol Cancer Ther 2003; 2: 445–51.
Oshima M, Oshima H, Matsunaga A, Taketo MM . Hyperplastic gastric tumors with spasmolytic polypeptide-expressing metaplasia caused by tumor necrosis factor-alpha-dependent inflammation in cyclooxygenase-2/microsomal prostaglandin E synthase-1 transgenic mice. Cancer Res 2005; 65: 9147–51.
Wheeler DL, Ness KJ, Oberley TD, Verma AK . Protein kinase Cepsilon is linked to 12-O-tetradecanoylphorbol-13-acetate-induced tumor necrosis factor-alpha ectodomain shedding and the development of metastatic squamous cell carcinoma in protein kinase Cepsilon transgenic mice. Cancer Res 2003; 63: 6547–55.
Suzukawa K, Weber TJ, Colburn NH . AP-1, NF-kappa-B, and ERK activation thresholds for promotion of neoplastic transformation in the mouse epidermal JB6 model. Environ Health Perspect 2002; 110: 865–70.
Hu J, Nakano H, Sakurai H, Colburn NH . Insufficient p65 phos-phorylation at S536 specifically contributes to the lack of NF-kappaB activation and transformation in resistant JB6 cells. Carcinogenesis 2004; 25: 1991–2003.
Arnott CH, Scott KA, Moore RJ, Hewer A, Phillips DH, Parker P, et al. Tumour necrosis factor-alpha mediates tumour promotion via a PKC alpha- and AP-1-dependent pathway. Oncogene 2002; 21: 4728–38.
Yang H, Bocchetta M, Kroczynska B, Elmishad AG, Chen Y, Liu Z, et al. TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis. Proc Natl Acad Sci USA 2006; 103: 10397–402.
Yan Y, Li J, Ouyang W, Ma Q, Hu Y, Zhang D, et al. NFAT3 is specifically required for TNF-alpha-induced cyclooxygenase-2 (COX-2) expression and transformation of C141 cells. J Cell Sci 2006; 119 ( Pt 14): 2985–94.
Devoogdt N, Revets H, Kindt A, Liu YQ, De Baetselier P, Ghassabeh GH . The tumor-promoting effect of TNF-alpha involves the induction of secretory leukocyte protease inhibitor. J Immunol 2006; 177: 8046–52.
Piao YS, Du YC, Oshima H, Jin JC, Nomura M, Yoshimoto T, et al. Platelet-type 12-lipoxygenase accelerates tumor promotion of mouse epidermal cells through enhancement of cloning efficiency. Carcinogenesis 2008; 29: 440–7.
Komori J, Marusawa H, Machimoto T, Endo Y, Kinoshita K, Kou T, et al. Activation-induced cytidine deaminase links bile duct inflammation to human cholangiocarcinoma. Hepatology 2008; 47: 888–96.
Yan B, Wang H, Rabbani ZN, Zhao Y, Li W, Yuan Y, et al. Tumor necrosis factor-alpha is a potent endogenous mutagen that promotes cellular transformation. Cancer Res 2006; 66: 11565–70.
Babbar N, Casero RA Jr . Tumor necrosis factor-alpha increases reactive oxygen species by inducing spermine oxidase in human lung epithelial cells: a potential mechanism for inflammation-induced carcinogenesis. Cancer Res 2006; 66: 11125–30.
Nabors LB, Suswam E, Huang Y, Yang X, Johnson MJ, King PH . Tumor necrosis factor alpha induces angiogenic factor up-regulation in malignant glioma cells: a role for RNA stabilization and HuR. Cancer Res 2003; 63: 4181–7.
Kulbe H, Thompson R, Wilson JL, Robinson S, Hagemann T, Fatah R, et al. The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Cancer Res 2007; 67: 585–92.
Tomita Y, Yang X, Ishida Y, Nemoto-Sasaki Y, Kondo T, Oda M, et al. Spontaneous regression of lung metastasis in the absence of tumor necrosis factor receptor p55. Int J Cancer 2004; 112: 927–33.
Bates RC, DeLeo MJ 3rd, Mercurio AM . The epithelial-mesen-chymal transition of colon carcinoma involves expression of IL-8 and CXCR-1-mediated chemotaxis. Exp Cell Res 2004; 299: 315–24.
Bates RC, Mercurio AM . Tumor necrosis factor-alpha stimulates the epithelial-to-mesenchymal transition of human colonic organoids. Mol Biol Cell 2003; 14: 1790–800.
Chuang MJ, Sun KH, Tang SJ, Deng MW, Wu YH, Sung JS, et al. Tumor-derived tumor necrosis factor-alpha promotes progression and epithelial-mesenchymal transition in renal cell carcinoma cells. Cancer Sci 2008; 99: 905–1.
Cheng SM, Xing B, Li JC, Cheung BK, Lau AS . Interferon-gamma regulation of TNFalpha-induced matrix metalloproteinase 3 expression and migration of human glioma T98G cells. Int J Cancer 2007; 121: 1190–6.
Esteve PO, Chicoine E, Robledo O, Aoudjit F, Descoteaux A, Potworowski EF, et al. Protein kinase C-zeta regulates transcription of the matrix metalloproteinase-9 gene induced by IL-1 and TNF-alpha in glioma cells via NF-kappa B. J Biol Chem 2002; 277: 35150–5.
Hagemann T, Robinson SC, Schulz M, Trumper L, Balkwill FR, Binder C . Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-alpha dependent up-regulation of matrix metalloproteases. Carcinogenesis 2004; 25: 1543–9.
Montesano R, Soulie P, Eble JA, Carrozzino F . Tumour necrosis factor alpha confers an invasive, transformed phenotype on mammary epithelial cells. J Cell Sci 2005; 118: 3487–500.
Mon NN, Hasegawa H, Thant AA, Huang P, Tanimura Y, Senga T, et al. A role for focal adhesion kinase signaling in tumor necrosis factor-alpha-dependent matrix metalloproteinase-9 production in a cholangiocarcinoma cell line, CCKS1. Cancer Res 2006; 66: 6778–84.
Hagemann T, Wilson J, Kulbe H, Li NF, Leinster DA, Charles K, et al. Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J Immunol 2005; 175: 1197–205.
Ziprin P, Ridgway PF, Pfistermuller KL, Peck DH, Darzi AW . ICAM-1 mediated tumor-mesothelial cell adhesion is modulated by IL-6 and TNF-alpha: a potential mechanism by which surgical trauma increases peritoneal metastases. Cell Commun Adhes 2003; 10: 141–54.
van Grevenstein WM, Holland LJ, van Rossen ME, van Koetsveld PM, Jeekel J, van Eijck CH . Inflammatory cytokines stimulate the adhesion of colon carcinoma cells to mesothelial monolayers. Dig Dis Sci 2007; 52: 2775–83.
Choo MK, Sakurai H, Koizumi K, Saiki I . TAKl-mediated stress signaling pathways are essential for TNF-alpha-promoted pulmonary metastasis of murine colon cancer cells. Int J Cancer 2006; 118: 2758–64.
Kitakata H, Nemoto-Sasaki Y, Takahashi Y, Kondo T, Mai M, Mukaida N . Essential roles of tumor necrosis factor receptor p55 in liver metastasis of intrasplenic administration of colon 26 cells. Cancer Res 2002; 62: 6682–7.
Kulbe H, Hagemann T, Szlosarek PW, Balkwill FR, Wilson JL . The inflammatory cytokine tumor necrosis factor-alpha regulates chemokine receptor expression on ovarian cancer cells. Cancer Res 2005; 65: 10355–62.
Mochizuki Y, Nakanishi H, Kodera Y, Ito S, Yamamura Y, Kato T, et al. TNF-alpha promotes progression of peritoneal metastasis as demonstrated using a green fluorescence protein (GFP)-tagged human gastric cancer cell line. Clin Exp Metastasis 2004; 21: 39–47.
Alkhamesi NA, Ziprin P, Pfistermuller K, Peck DH, Darzi AW . ICAM-1 mediated peritoneal carcinomatosis, a target for therapeutic intervention. Clin Exp Metastasis 2005; 22: 449–59.
Liang M, Zhang P, Fu J . Up-regulation of LOX-1 expression by TNF-alpha promotes trans-endothelial migration of MDA-MB-231 breast cancer cells. Cancer Lett 2007; 258: 31–7.
Swann JB, Vesely MD, Silva A, Sharkey J, Akira S, Schreiber RD, et al. Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proc Natl Acad Sci USA 2008; 105: 652–6.
Nakagawa J, Saio M, Tamakawa N, Suwa T, Frey AB, Nonaka K, et al. TNF expressed by tumor-associated macrophages, but not microglia, can eliminate glioma. Int J Oncol 2007; 30: 803–11.
Villeneuve J, Tremblay P, Vallieres L . Tumor necrosis factor reduces brain tumor growth by enhancing macrophage recruitment and microcyst formation. Cancer Res 2005; 65: 3928–36.
Dace DS, Chen PW, Niederkorn JY CD8+ T cells circumvent immune privilege in the eye and mediate intraocular tumor rejection by a TNF-alpha-dependent mechanism. J Immunol 2007; 178: 6115–22.
Zhang B, Karrison T, Rowley DA, Schreiber H . IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers. J Clin Invest 2008; 118: 1398–404.
Larmonier N, Cathelin D, Larmonier C, Nicolas A, Merino D, Janikashvili N, et al. The inhibition of TNF-alpha anti-tumoral properties by blocking antibodies promotes tumor growth in a rat model. Exp Cell Res 2007; 313: 2345–55.
Zhao X, Mohaupt M, Jiang J, Liu S, Li B, Qin Z . Tumor necrosis factor receptor 2-mediated tumor suppression is nitric oxide dependent and involves angiostasis. Cancer Res 2007; 67: 4443–50.
Karin M, Lawrence T, Nizet V . Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell 2006; 124: 823–35.
Stone JH, Holbrook JT, Marriott MA, Tibbs AK, Sejismundo LP, Min YI, et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum 2006; 54: 1608–18.
Shibata H, Yoshioka Y, Ikemizu S, Kobayashi K, Yamamoto Y, Mukai Y, et al. Functionalization of tumor necrosis factor-alpha using phage display technique and PEGylation improves its antitumor therapeutic window. Clin Cancer Res 2004; 10: 8293–300.
Lucas R, Montesano R, Pepper MS, Hafner M, Sablon E, Dunant Y, et al. Lectin-deficient TNF mutants display comparable anti-tumour but reduced pro-metastatic potential as compared to the wild-type molecule. Int J Cancer 2001; 91: 543–9.
Yan Z, Zhao N, Wang Z, Li B, Bao C, Shi J, et al. A mutated human tumor necrosis factor-alpha improves the therapeutic index in vitro and in vivo. Cytotherapy 2006; 8: 415–23.
Wang X, Ju W, Renouard J, Aden J, Belinsky SA, Lin Y 17-allyl-amino-17-demethoxygeldanamycin synergistically potentiates tumor necrosis factor-induced lung cancer cell death by blocking the nuclear factor-kappa B pathway. Cancer Res 2006; 66: 1089–95.
Zhang S, Lin ZN, Yang CF, Shi X, Ong CN, Shen HM . Suppressed NF-kappaB and sustained JNK activation contribute to the sensitization effect of parthenolide to TNF-alpha-induced apoptosis in human cancer cells. Carcinogenesis 2004; 25: 2191–9.
Fas SC, Baumann S, Zhu JY, Giaisi M, Treiber MK, Mahlknecht U, et al. Wogonin sensitizes resistant malignant cells to TNFalpha- and TRAIL-induced apoptosis. Blood 2006; 108: 3700–6.
Ju W, Wang X, Shi H, Chen W, Belinsky SA, Lin YA critical role of luteolin-induced reactive oxygen species in blockage of tumor necrosis factor-activated nuclear factor-kappa B pathway and sensitization of apoptosis in lung cancer cells. Mol Pharmacol 2007; 71: 1381–8.
Rae C, Langa S, Tucker SJ, MacEwan DJ . Elevated NF-kappa B responses and FLIP levels in leukemic but not normal lymphocytes: reduction by salicylate allows TNF-induced apoptosis. Proc Natl Acad Sci USA 2007; 104: 12790–5.
Shukla S, Gupta S . Suppression of constitutive and tumor necrosis factor alpha-induced nuclear factor (NF)-kappa B activation and induction of apoptosis by apigenin in human prostate carcinoma PC-3 cells: correlation with down-regulation of NF-kappaB-responsive genes. Clin Cancer Res 2004; 10: 3169–78.
Shishodia S, Sethi G, Konopleva M, Andreeff M, Aggarwal BB . A synthetic triterpenoid, CDDO-Me, inhibits IkappaBalpha kinase and enhances apoptosis induced by TNF and chemotherapeutic agents through down-regulation of expression of nuclear factor kappaB-regulated gene products in human leukemic cells. Clin Cancer Res 2006; 12: 1828–38.
Wang X, Chen W, Lin Y Sensitization of TNF-induced cytotoxicity in lung cancer cells by concurrent suppression of the NF-kappaB and Akt pathways. Biochem Biophys Res Commun 2007; 355: 807–12.
Duverger V, Murphy AM, Sheehan D, England K, Cotter TG, Hayes I, et al. The anticancer drug mithramycin A sensitises tumour cells to apoptosis induced by tumour necrosis factor (TNF). Br J Cancer 2004; 90: 2025–31.
Mathiasen IS, Hansen CM, Foghsgaard L, Jaattela M . Sensitization to TNF-induced apoptosis by 1,25-dihydroxy vitamin D(3) involves up-regulation of the TNF receptor 1 and cathepsin B. Int J Cancer 2001; 93: 224–31.
Cao W, Chi WH, Wang J, Tang JJ, Lu YJ . TNF-alpha promotes Doxorubicin-induced cell apoptosis and anti-cancer effect through downregulation of p21 in p53-deficient tumor cells. Biochem Biophys Res Commun 2005; 330: 1034–40.
Hambek M, Solbach C, Schnuerch HG, Roller M, Stegmueller M, Sterner-Kock A, et al. Tumor necrosis factor alpha sensitizes low epidermal growth factor receptor (EGFR)-expressing carcinomas for anti-EGFR therapy. Cancer Res 2001; 61: 1045–9.
Ando K, Ohmori T, Inoue F, Kadofuku T, Hosaka T, Ishida H, et al. Enhancement of sensitivity to tumor necrosis factor alpha in non-small cell lung cancer cells with acquired resistance to gefitinib. Clin Cancer Res 2005; 11: 8872–9.
Hayes AJ, Neuhaus SJ, Clark MA, Thomas JM . Isolated limb perfusion with melphalan and tumor necrosis factor alpha for advanced melanoma and soft-tissue sarcoma. Ann Surg Oncol 2007; 14: 230–8.
Grunhagen DJ, de Wilt JH, ten Hagen TL, Eggermont AM . Technology insight: Utility of TNF-alpha-based isolated limb perfusion to avoid amputation of irresectable tumors of the extremities. Nat Clin Pract Oncol 2006; 3: 94–103.
Lans TE, Grunhagen DJ, de Wilt JH, van Geel AN, Eggermont AM . Isolated limb perfusions with tumor necrosis factor and melphalan for locally recurrent soft tissue sarcoma in previously irradiated limbs. Ann Surg Oncol 2005; 12: 406–11.
Farma JM, Puhlmann M, Soriano PA, Cox D, Paciotti GF, Tamarkin L, et al. Direct evidence for rapid and selective induction of tumor neovascular permeability by tumor necrosis factor and a novel derivative, colloidal gold bound tumor necrosis factor. Int J Cancer 2007; 120: 2474–80.
Menon C, Iyer M, Prabakaran I, Canter RJ, Lehr SC, Fraker DL . TNF-alpha downregulates vascular endothelial Flk-1 expression in human melanoma xenograft model. Am J Physiol Heart Circ Physiol 2003; 284: H317–29.
Rossi CR, Mocellin S, Pilati P, Foletto M, Campana L, Quintieri L, et al. Hyperthermic isolated perfusion with low-dose tumor necrosis factor alpha and doxorubicin for the treatment of limb-threatening soft tissue sarcomas. Ann Surg Oncol 2005; 12: 398–405.
Di Filippo F, Garinei R, Anza M, Cavaliere F, Giannarelli D, Cagol PP, et al. Doxorubicin in isolation limb perfusion in the treatment of advanced limb soft tissue sarcoma. J Exp Clin Cancer Res 2003; 22 ( 4 Suppl): 81–7.
van Etten B, de Vries MR, van IMG, Lans TE, Guetens G, Amba-gtsheer G, et al. Degree of tumour vascularity correlates with drug accumulation and tumour response upon TNF-alpha-based isolated hepatic perfusion. Br J Cancer 2003; 88: 314–9.
Oshiro S, Tsugu H, Komatsu F, Ohnishi H, Ueno Y, Sakamoto S, et al. Evaluation of intratumoral administration of tumor necrosis factor-alpha in patients with malignant glioma. Anticancer Res 2006; 26: 4027–32.
Cornett WR, McCall LM, Petersen RP, Ross MI, Briele HA, Noyes RD, et al. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol 2006; 24: 4196–201.
McLoughlin JM, McCarty TM, Cunningham C, Clark V, Senzer N, Nemunaitis J, et al. TNFerade, an adenovector carrying the transgene for human tumor necrosis factor alpha, for patients with advanced solid tumors: surgical experience and long-term follow-up. Ann Surg Oncol 2005; 12: 825–30.
Lopez CA, Kimchi ET, Mauceri HJ, Park JO, Mehta N, Murphy KT, et al. Chemoinducible gene therapy: a strategy to enhance doxorubicin antitumor activity. Mol Cancer Ther 2004; 3: 1167–75.
Gupta VK, Park JO, Jaskowiak NT, Mauceri HJ, Seetharam S, Weichselbaum RR, et al. Combined gene therapy and ionizing radiation is a novel approach to treat human esophageal adeno-carcinoma. Ann Surg Oncol 2002; 9: 500–4.
Yamini B, Yu X, Pytel P, Galanopoulos N, Rawlani V, Veerapong J, et al. Adenovirally delivered tumor necrosis factor-alpha improves the antiglioma efficacy of concomitant radiation and temozolomide therapy. Clin Cancer Res 2007; 13: 6217–23.
Bickenbach KA, Veerapong J, Shao MY, Mauceri HJ, Posner MC, Kron SJ, et al. Resveratrol is an effective inducer of CArG-driven TNF-alpha gene therapy. Cancer Gene Ther 2008; 15: 133–9.
MacGill RS, Davis TA, Macko J, Mauceri HJ, Weichselbaum RR, King CR . Local gene delivery of tumor necrosis factor alpha can impact primary tumor growth and metastases through a host-mediated response. Clin Exp Metastasis 2007; 24: 521–31.
Murugesan SR, Akiyama M, Einfeld DA, Wickham TJ, King CR . Experimental treatment of ovarian cancers by adenovirus vectors combining receptor targeting and selective expression of tumor necrosis factor. Int J Oncol 2007; 31: 813–22.
Han ZQ, Assenberg M, Liu BL, Wang YB, Simpson G, Thomas S, et al. Development of a second-generation oncolytic Herpes simplex virus expressing TNFalpha for cancer therapy. J Gene Med 2007; 9: 99–106.
Li Q, Li L, Shi W, Jiang X, Xu Y, Gong F, et al. Mechanism of action differences in the antitumor effects of transmembrane and secretory tumor necrosis factor-alpha in vitro and in vivo. Cancer Immunol Immunother 2006; 55: 1470–9.
Lyu MA, Rosenblum MG . The immunocytokine scFv23/TNF sensitizes HER-2/neu-overexpressing SKBR-3 cells to tumor necrosis factor (TNF) via up-regulation of TNF receptor-1. Mol Cancer Ther 2005; 4: 1205–13.
Liu Y, Zhang W, Cheung LH, Niu T, Wu Q, Li C, et al. The antime-lanoma immunocytokine scFvMEL/TNF shows reduced toxicity and potent antitumor activity against human tumor xenografts. Neoplasia 2006; 8: 384–93.
Christ O, Seiter S, Matzku S, Burger C, Zoller M . Efficacy of local versus systemic application of antibody-cytokine fusion proteins in tumor therapy. Clin Cancer Res 2001; 7: 985–98.
Halin C, Gafner V, Villani ME, Borsi L, Berndt A, Kosmehl H, et al. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha. Cancer Res 2003; 63: 3202–10.
Larbouret C, Robert B, Linard C, Teulon I, Gourgou S, Bibeau F, et al. Radiocurability by targeting tumor necrosis factor-alpha using a bispecific antibody in carcinoembryonic antigen transgenic mice. Int J Radiat Oncol Biol Phys 2007; 69: 1231–7.
Zarovni N, Monaco L, Corti A . Inhibition of tumor growth by intramuscular injection of cDNA encoding tumor necrosis factor alpha coupled to NGR and RGD tumor-homing peptides. Hum Gene Ther 2004; 15: 373–82.
Sacchi A, Gasparri A, Gallo-Stampino C, Toma S, Curnis F, Corti A . Synergistic antitumor activity of cisplatin, paclitaxel, and gemcitabine with tumor vasculature-targeted tumor necrosis factor-alpha. Clin Cancer Res 2006; 12: 175–82.
Curnis F, Gasparri A, Sacchi A, Longhi R, Corti A . Coupling tumor necrosis factor-alpha with alphaV integrin ligands improves its antineoplastic activity. Cancer Res 2004; 64: 565–71.
Curnis F, Sacchi A, Corti A . Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J Clin Invest 2002; 110: 475–82.
van Laarhoven HW, Gambarota G, Heerschap A, Lok J, Verhagen I, Corti A, et al. Effects of the tumor vasculature targeting agent NGR-TNF on the tumor microenvironment in murine lymphomas. Invest New Drags 2006; 24: 27–36.
Sacchi A, Gasparri A, Curnis F, Bellone M, Corti A . Crucial role for interferon gamma in the synergism between tumor vasculature-targeted tumor necrosis factor alpha (NGR-TNF) and doxorubicin. Cancer Res 2004; 64: 7150–5.
Kircheis R, Ostermann E, Wolschek MF, Lichtenberger C, Magin-Lachmann C, Wightman L, et al. Tumor-targeted gene delivery of tumor necrosis factor-alpha induces tumor necrosis and tumor regression without systemic toxicity. Cancer Gene Ther 2002; 9: 673–80.
ten Hagen TL, Seynhaeve AL, van Tiel ST, Ruiter DJ, Eggermont AM . Pegylated liposomal tumor necrosis factor-alpha results in reduced toxicity and synergistic antitumor activity after systemic administration in combination with liposomal doxorubicin (Doxil) in soft tissue sarcoma-bearing rats. Int J Cancer 2002; 97: 115–20.
Kim DW, Andres ML, Miller GM, Cao JD, Green LM, Seynhaeve AL, et al. Immunohistological analysis of immune cell infiltration of a human colon tumor xenograft after treatment with Stealth liposome-encapsulated tumor necrosis factor-alpha and radiation. Int J Oncol 2002; 21: 973–9.
Goel R, Swanlund D, Coad J, Paciotti GF, Bischof JC . TNF-alpha-based accentuation in cryoinjury-dose, delivery, and response. Mol Cancer Ther 2007; 6: 2039–47.
Visaria RK, Griffin RJ, Williams BW, Ebbini ES, Paciotti GF, Song CW, et al. Enhancement of tumor thermal therapy using gold nanoparticle-assisted tumor necrosis factor-alpha delivery. Mol Cancer Ther 2006; 5: 1014–20.
Kianmanesh A, Hackett NR, Lee JM, Kikuchi T, Korst RJ, Crystal RG . Intratumoral administration of low doses of an adenovirus vector encoding tumor necrosis factor alpha together with naive dendritic cells elicits significant suppression of tumor growth without toxicity. Hum Gene Ther 2001; 12: 2035–49.
Liu Y, Saxena A, Zheng C, Carlsen S, Xiang J . Combined alpha tumor necrosis factor gene therapy and engineered dendritic cell vaccine in combating well-established tumors. J Gene Med 2004; 6: 857–68.
Lu Y, Yamauchi N, Koshita Y, Fujiwara H, Sato Y, Fujii S, et al. Administration of subtumor regression dosage of TNF-alpha to mice with pre-existing parental tumors augments the vaccination effect of TNF gene-modified tumor through the induction of MHC class I molecule. Gene Ther 2001; 8: 499–507.
Chen S, Fribley A, Wang CY . Potentiation of tumor necrosis factor-mediated apoptosis of oral squamous cell carcinoma cells by adenovirus-mediated gene transfer of NF-kappaB inhibitor. J Dent Res 2002; 81: 98–102.
Ye Z, Shi M, Chan T, Sas S, Xu S, Xiang J . Engineered CD8+ cytotoxic T cells with fiber-modified adenovirus-mediated TNF-alpha gene transfection counteract immunosuppressive interleukin-10-secreting lung metastasis and solid tumors. Cancer Gene Ther 2007; 14: 661–75.
Lasek W, Mackiewicz A, Czajka A, Switaj T, Golb J, Wiznerowicz M, et al. Antitumor effects of the combination therapy with TNF-alpha gene-modified tumor cells and interleukin 12 in a melanoma model in mice. Cancer Gene Ther 2000; 7: 1581–90.
Nagy T, Glavinas H, Szincsak N, Hunyadi J, Janossy T, Duda E, et al. Tumor cells expressing membrane-bound tumor necrosis factor activate macrophages and have a compromised growth in immunosuppressed and immunodeficient mice. Cancer Lett 2003; 196: 49–56.
Zimmermann VS, Bondanza A, Monno A, Rovere-Querini P, Corti A, Manfredi AA . TNF-alpha coupled to membrane of apoptotic cells favors the cross-priming to melanoma antigens. J Immunol 2004; 172: 2643–50.
Egberts JH, Cloosters V, Noack A, Schniewind B, Thon L, Klose S, et al. Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis. Cancer Res 2008; 68: 1443–50.
Madhusudan S, Foster M, Muthuramalingam SR, Braybrooke JP, Wilner S, Kaur K, et al. A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer. Clin Cancer Res 2004; 10: 6528–34.
Madhusudan S, Muthuramalingam SR, Braybrooke JP, Wilner S, Kaur K, Han C, et al. Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer. J Clin Oncol 2005; 23: 5950–9.
Harrison ML, Obermueller E, Maisey NR, Hoare S, Edmonds K, Li NF, et al. Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. J Clin Oncol 2007; 25: 4542–9.
Stathopoulos GT, Kollintza A, Moschos C, Psallidas I, Sherrill TP, Pitsinos EN, et al. Tumor necrosis factor-alpha promotes malignant pleural effusion. Cancer Res 2007; 67: 9825–34.
Waterston AM, Salway F, Andreakos E, Butler DM, Feldmann M, Coombes RC . TNF auto vaccination induces self anti-TNF antibodies and inhibits metastasis in a murine melanoma model. Br J Cancer 2004; 90: 1279–84.
Geborek P, Bladstrom A, Turesson C, Gulfe A, Petersson IF, Saxne T, et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 2005; 64: 699–703.
Calzascia T, Pellegrini M, Hall H, Sabbagh L, Ono N, Elford AR, et al. TNF-alpha is critical for antitumor but not antiviral T cell immunity in mice. J Clin Invest 2007; 117: 3833–45.
Vince JE, Wong WW, Khan N, Feltham R, Chau D, Ahmed AU, et al. IAP antagonists target cIAPl to induce TNFalpha-dependent apoptosis. Cell 2007; 131: 682–93.
Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N, Garg P, et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNF alpha-dependent apoptosis. Cell 2007; 131: 669–81.
This study is partly supported by grants from the National Cancer Institute (R03CA125796, to Yong Lin), and National Natural Science Foundation of China (30772539, to Xia Wang).
Rights and permissions
About this article
Cite this article
Wang, X., Lin, Y. Tumor necrosis factor and cancer, buddies or foes?. Acta Pharmacol Sin 29, 1275–1288 (2008). https://doi.org/10.1111/j.1745-7254.2008.00889.x
- signaling pathways
This article is cited by
Investigation of the gut microbiome, bile acid composition and host immunoinflammatory response in a model of azoxymethane-induced colon cancer at discrete timepoints
British Journal of Cancer (2023)
Drug repurposing: re-inventing therapies for cancer without re-entering the development pipeline—a review
Journal of the Egyptian National Cancer Institute (2022)
BCL2A1 regulates Canady Helios Cold Plasma-induced cell death in triple-negative breast cancer
Scientific Reports (2022)
Optogenetic-controlled immunotherapeutic designer cells for post-surgical cancer immunotherapy
Nature Communications (2022)
An in silico comparative transcriptome analysis identifying hub lncRNAs and mRNAs in brain metastatic small cell lung cancer (SCLC)
Scientific Reports (2022)